Minutes of ABPI and CSM annual meeting re i Study on control medicines ii Current status of licensing procedures iii Hearings iv Expert reports v Quality of applications vi Rationalising the volume of clinical documentation for marketing authorisation applications vii Preclinical data for Biotechnology Products viii Draft COM mutagenicity guidelines ix Adverse reaction reporting and post marketing surveillance x Inverted black triangles xi Post marketing surveillance and xii Patient information